2021
DOI: 10.1093/infdis/jiab098 View full text |Buy / Rent full text
|
|

Abstract: Background Currently, there is no specific drug for the treatment of COVID-19. Therapeutic benefits of intravenous immunoglobin (IVIG) have been demonstrated in wide range of diseases. The present study is conducted to evaluate the safety and efficacy of IVIG in the treatment of COVID-19 patients with moderate pneumonia. Methods An open-label, multicenter, comparative, randomized study was conducted on COVID-19 patients with … Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
0
29
0

Publication Types

Select...

Relationship

0
0

Authors

Journals